Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research, Inc. | PRODUCT CODE: 1030886

Cover Image

PUBLISHER: Grand View Research, Inc. | PRODUCT CODE: 1030886

Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's), By Type (Genomic, Proteomic), By End-use, By Region, And Segment Forecasts, 2021 - 2028

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Neurological Biomarkers Market Growth & Trends:

The global neurological biomarkers market size is expected to reach USD 16.14 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 12.9% from 2020 to 2028. Increasing funding for the R&D of neurological biomarkers to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products for the diagnosis of neurological biomarkers is expected to propel market growth over the forecast period.

The National Institute of Neurological Disorders and Stroke provides funding, such as development grants & cooperative agreements for researchers conducting studies related to biomarker discovery, analytical validation, & clinical validation. Thus, the presence of organizations offering funds at various stages of research is anticipated to drive market growth. For instance, the University of North Texas Health Science Center (HSC) was awarded around USD 45.5 million funds from the National Institutes of Health (NIH) to support research regarding health disparities in Alzheimer's and brain aging. NIH is offering additional funds for biomarkers research for the ongoing Health and Aging Brain Among Latino Elders (HABLE) study.

Increasing product launches are also expected to drive market growth. For instance, in January 2021, Abbott received FDA 510K clearance for its rapid handheld traumatic brain injury test that measures UCH-L1 and GFAP biomarkers. The results of this test are available within 15 minutes, and it helps clinicians assess the need to perform a CT scan. The rapid turnaround time of this test will help physicians plan and deliver treatment on time.

In August 2018, Olink Proteomics AB introduced a new biomarker panel Olink NEURO EXPLORATORY for the expansion of a portfolio of high-quality protein assays. This product includes a high-performance assay for neurofilament light polypeptide, a significant biomarker for traumatic brain injury and degenerative neurological diseases.

However, the lack of reimbursement coverage for the biomarkers impedes the market growth. Currently, only certain, restricted forms of biomarker tests for dementia symptoms are covered by Medicare and other health insurance programs and their use must be justified based on the symptoms and specific requirements of the individual.

The reimbursement for Alzheimer's disease is also not provided by most of the insurance providers, such as the Blue Cross and Blue Shield Association. The reimbursement coverage for neurological biomarker testing in developing countries, such as India and China, is even lesser, as these countries have low insurance penetration and very little awareness about biomarker testing.

Neurological Biomarkers Market Report Highlights:

  • Increasing collaborations and public-private partnerships for research initiatives may fuel market growth
  • For instance, in February 2018, MJFF in collaboration with the NIH and five life-sciences companies provided USD 24 million as a research grant for the development of neurological biomarkers
  • In 2020, the proteomic biomarkers segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period
  • The Parkinson's disease segment led the market in 2020. An increasing number of clinical trials for Parkinson's disease drugs and the growing prevalence of the disease is expected to drive the segment growth in the years to come
  • North America was the largest regional market in 2020 owing to the high disease burden, acceptance of biomarkers for diagnostic, prognostics, & drug development purposes, and increase in research funding
  • Asia Pacific is anticipated to witness the fastest CAGR over the forecast period owing to a rising number of clinical trials being conducted in developing countries, such as India and China, increasing disease burden, and growing need for targeted drugs in the central nervous system
Product Code: GVR-3-68038-823-7

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 Neurological Biomarkers Market Variables, Trends, and Scope

  • 3.1 Neurological Biomarkers Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Pipeline Analysis
    • 3.3.1 Alzheimer's Disease
    • 3.3.2 Parkinson's Disease
    • 3.3.3 Multiple Sclerosis
    • 3.3.4 Autism Spectrum Disorder
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Increasing Prevalence Of Neurological Diseases
      • 3.4.1.2 Technological Advancements
      • 3.4.1.3 Increased Funding For R&D In Biomarkers
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 Lack of consumer awareness
      • 3.4.2.2 Reimbursement policies
  • 3.5 Neurological Biomarkers: Market Analysis Tools
    • 3.5.1 Industry Analysis - Porter's
    • 3.5.2 Pestle Analysis

Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2017 - 2028 (USD Million)

  • 4.1 Definition and Scope
  • 4.2 Type Market Share Analysis, 2020 & 2028
  • 4.3 Segment Dashboard
  • 4.4 Global Neurological Biomarkers Market, by Type, 2017 to 2028
  • 4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
    • 4.5.1 Genomic
      • 4.5.1.1 Genomic Neurological Biomarkers Market, 2017 - 2028 (USD Million)
    • 4.5.2 Proteomic
      • 4.5.2.1 Proteomic Neurological Biomarkers Market, 2017 - 2028 (USD Million)
    • 4.5.3 Metabolomic
      • 4.5.3.1 Metabolomic Neurological Biomarkers Market, 2017 - 2028 (USD Million)
    • 4.5.4 Imaging
      • 4.5.4.1 Imaging Market Estimates And Forecast, 2016 - 2028 (USD Million)
    • 4.5.5 Others
      • 4.5.5.1 Others market, 2017 - 2028 (USD Million)

Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2017 - 2028 (USD Million)

  • 5.1 Definition and Scope
  • 5.2 Application Market Share Analysis, 2020 & 2028
  • 5.3 Segment Dashboard
  • 5.4 Global Neurological Biomarkers Market, by Application, 2017 to 2028
  • 5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
    • 5.5.1 Alzheimer's Disease
      • 5.5.1.1 Alzheimer's Disease Market, 2017 - 2028 (USD Million)
    • 5.5.2 Parkinson's Disease
      • 5.5.2.1 Parkinson's Disease Market, 2017 - 2028 (USD Million)
    • 5.5.3 Multiple Sclerosis
      • 5.5.3.1 Multiple Sclerosis Market, 2017 - 2028 (USD Million)
    • 5.5.4 Autism Spectrum Disorder
      • 5.5.4.1 Autism Spectrum Disorder Market, 2017 - 2028 (USD Million)
    • 5.5.5 Others
      • 5.5.5.1 Others market, 2017 - 2028 (USD Million)

Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End Use, 2017 - 2028 (USD Million)

  • 6.1 Definition and Scope
  • 6.2 End-use Market Share Analysis, 2020 & 2028
  • 6.3 Segment Dashboard
  • 6.4 Global Neurological Biomarkers Market, by End Use, 2017 to 2028
  • 6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
    • 6.5.1 Hospital & Hospital Laboratories
      • 6.5.1.1 Hospitals & Hospital Laboratories Market, 2017 - 2028 (USD Million)
    • 6.5.2 Independent Clinical Diagnostic Centers
      • 6.5.2.1 Independent Clinical Diagnostic Centers Market, 2017 - 2028 (USD Million)
    • 6.5.3 Research Organizations And Others
      • 6.5.3.1 Research Organizations and Others market, 2017 - 2028 (USD Million)

Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2017 - 2028 (USD Million)

  • 7.1 Definition & Scope
  • 7.2 Regional Market Share Analysis, 2020 & 2028
  • 7.3 Regional Market Dashboard
  • 7.4 Regional Market Snapshot
  • 7.5 Regional Market Share and Leading Players, 2020
    • 7.5.1 North America
    • 7.5.2 Europe
    • 7.5.3 Asia Pacific
    • 7.5.4 Latin America
    • 7.5.5 Middle East And Africa
  • 7.6 SWOT Analysis
    • 7.6.1 NORTH AMERICA
    • 7.6.2 Europe
    • 7.6.3 Asia Pacific
    • 7.6.4 Latin America
    • 7.6.5 Middle East And Africa
  • 7.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2020 to 2028
    • 7.7.1 North America
      • 7.7.1.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
      • 7.7.1.2 The U.S.
      • 7.7.1.2.1 The U.S. Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.1.3 Canada
      • 7.7.1.3.1 Canada Neurological Biomarkers market, 2017 - 2028 (USD Million)
    • 7.7.2 Europe
      • 7.7.2.1 Europe Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.2.2 The U.K.
      • 7.7.2.2.1 The U.K. Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.2.3 Germany
      • 7.7.2.3.1 Germany Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.2.4 Spain
      • 7.7.2.4.1 Spain Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.2.5 France
      • 7.7.2.5.1 France Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.2.6 Italy
      • 7.7.2.6.1 Italy Neurological Biomarkers market, 2017 - 2028 (USD Million)
    • 7.7.3 Asia Pacific
      • 7.7.3.1 Asia Pacific Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.3.2 Japan
      • 7.7.3.2.1 Japan Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.3.3 China
      • 7.7.3.3.1 China Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.3.4 India
      • 7.7.3.4.1 India Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.3.5 South Korea
      • 7.7.3.5.1 South Korea Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.3.6 Australia
      • 7.7.3.6.1 Australia Neurological Biomarkers market, 2017 - 2028 (USD Million)
    • 7.7.4 Latin America
      • 7.7.4.1 Latin America Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.4.2 Brazil
      • 7.7.4.2.1 Brazil Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.4.3 Mexico
      • 7.7.4.3.1 Mexico Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.4.4 Argentina
      • 7.7.4.4.1 Argentina Neurological Biomarkers market, 2017 - 2028 (USD Million)
    • 7.7.5 MEA
      • 7.7.5.1 MEA Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.5.2 South Africa
      • 7.7.5.2.1 South Africa Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.5.3 Saudi Arabia
      • 7.7.5.3.1 Saudi Arabia Neurological Biomarkers market, 2017 - 2028 (USD Million)
      • 7.7.5.4 UAE
      • 7.7.5.4.1 UAE Neurological Biomarkers market, 2017 - 2028 (USD Million)

Chapter 8 Neurological Biomarkers Market: Competitive Analysis

  • 8.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 8.1.1 New Product Launches
    • 8.1.2 Mergers And Acquisitions
    • 8.1.3 Partnerships And Licensing Agreements
    • 8.1.4 Conferences And Campaigns
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market Leaders
    • 8.2.3 Heat Map Analysis
  • 8.3 Vendor Landscape
    • 8.3.1 List Of Key Distributors And Channel Partners
    • 8.3.2 Key Customers
  • 8.4 Public Companies
    • 8.4.1 Company Market Position Analysis
    • 8.4.2 Company Market Position Analysis
    • 8.4.3 Competitive Dashboard Analysis
      • 8.4.3.1 Market Differentiators
  • 8.5 Private Companies
    • 8.5.1 List Of Key Emerging Companies
  • 8.6 Company Profiles
    • 8.6.1 ABBOTT
      • 8.6.1.1 Company overview
      • 8.6.1.2 Financial performance
      • 8.6.1.3 Product benchmarking
      • 8.6.1.4 Strategic initiatives
    • 8.6.2 JOHNSON & JOHNSON SERVICES, INC.
      • 8.6.2.1 Company overview
      • 8.6.2.2 Financial performance
      • 8.6.2.3 Product benchmarking
      • 8.6.2.4 Strategic initiatives
    • 8.6.3 BIO-RAD LABORATORIES, INC.
      • 8.6.3.1 Company overview
      • 8.6.3.2 Financial performance
      • 8.6.3.3 Product benchmarking
      • 8.6.3.4 Strategic initiatives
    • 8.6.4 ALSERES PHARMACEUTICALS, INC.
      • 8.6.4.1 Company overview
      • 8.6.4.2 Product benchmarking
      • Pipeline candidate
    • 8.6.5 BANYAN BIOMARKERS, INC.
      • 8.6.5.1 Company overview
      • 8.6.5.2 Product benchmarking
      • 8.6.5.3 Strategic initiatives
    • 8.6.6 MYRIAD RBM (MYRIAD GENETICS, INC.)
      • 8.6.6.1 Company overview
      • 8.6.6.2 Financial performance
      • 8.6.6.3 Product benchmarking
      • 8.6.6.4 Strategic initiatives
    • 8.6.7 THERMO FISHER SCIENTIFIC, INC.
      • 8.6.7.1 Company overview
      • 8.6.7.2 Financial performance
      • 8.6.7.3 Product benchmarking
      • 8.6.7.4 Strategic initiatives
    • 8.6.8 DIAGENIC ASA
      • 8.6.8.1 Company overview
      • 8.6.8.2 Product benchmarking
    • 8.6.9 MERCK & CO., INC.
      • 8.6.9.1 Company overview
      • 8.6.9.2 Financial performance
      • 8.6.9.3 Product benchmarking
      • 8.6.9.4 Strategic initiatives
    • 8.6.10 QUANTERIX
      • 8.6.10.1 Company overview
      • 8.6.10.2 Product benchmarking
      • 8.6.10.3 Strategic initiatives
Product Code: GVR-3-68038-823-7

List of Tables

  • TABLE 1 List of Abbreviation
  • TABLE 2 North America neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 3 North America neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 4 North America neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 5 The U.S. neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 6 The U.S. neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 7 The U.S. neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 8 Canada neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 9 Canada neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 10 Canada neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 11 Europe neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 12 Europe neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 13 Europe neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 14 The U.K. neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 15 The U.K. neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 16 The U.K. neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 17 Germany neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 18 Germany neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 19 Germany neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 20 France neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 21 France neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 22 France neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 23 Italy neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 24 Italy neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 25 Italy neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 26 Spain neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 27 Spain neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 28 Spain neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 29 Asia Pacific neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 30 Asia Pacific neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 31 Asia Pacific neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 32 Japan neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 33 Japan neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 34 Japan neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 35 China neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 36 China neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 37 China neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 38 India neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 39 India neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 40 India neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 41 South Korea neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 42 South Korea neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 43 South Korea neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 44 Australia neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 45 Australia neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 46 Australia neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 47 Latin America neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 48 Latin America neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 49 Latin America neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 50 Brazil neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 51 Brazil neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 52 Brazil neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 53 Mexico neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 54 Mexico neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 55 Mexico neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 56 Argentina neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 57 Argentina neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 58 Argentina neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 59 MEA neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 60 MEA neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 61 MEA neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 62 South Africa neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 63 South Africa neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 64 South Africa neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 65 Saudi Arabia neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 66 Saudi Arabia neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 67 Saudi Arabia neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 68 UAE neurological biomarkers market, by application, 2017 - 2028 (USD Million)
  • TABLE 69 UAE neurological biomarkers market, by type, 2017 - 2028 (USD Million)
  • TABLE 70 UAE neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market size and growth prospects
  • FIG. 6 Global neurological biomarkers market- Key market driver analysis
  • FIG. 7 Global neurological biomarkers market - Key market restraint analysis
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 Global neurological biomarkers market - Porter's analysis
  • FIG. 10 Global neurological biomarkers market - PESTEL analysis
  • FIG. 11 Global neurological biomarkers market application outlook key takeaways
  • FIG. 12 Global neurological biomarkers market: Application movement analysis
  • FIG. 13 Alzheimer's disease market estimates, 2017 - 2028 (USD Million)
  • FIG. 14 Parkinson's disease market estimates, 2017 - 2028 (USD Million)
  • FIG. 15 Multiple sclerosis market estimates, 2017 - 2028 (USD Million)
  • FIG. 16 Autism spectrum disorders market estimates, 2017 - 2028 (USD Million)
  • FIG. 17 Others market estimates, 2017 - 2028 (USD Million)
  • FIG. 18 Global neurological biomarkers market type outlook key takeaways
  • FIG. 19 Global neurological biomarkers market: Type movement analysis
  • FIG. 20 Genomic market estimates, 2017 - 2028 (USD Million)
  • FIG. 21 Proteomic market estimates, 2017 - 2028 (USD Million)
  • FIG. 22 Metabolomic market estimates, 2017 - 2028 (USD Million)
  • FIG. 23 Imaging market estimates, 2017 - 2028 (USD Million)
  • FIG. 24 Others market estimates, 2017 - 2028 (USD Million)
  • FIG. 25 Global neurological biomarkers market end-use outlook key takeaways
  • FIG. 26 Global neurological biomarkers market: End-use movement analysis
  • FIG. 27 Hospital laboratories market estimates, 2017 - 2028 (USD Million)
  • FIG. 28 Independent clinical diagnostic centers market estimates, 2017 - 2028 (USD Million)
  • FIG. 29 Research organizations market estimates, 2017 - 2028 (USD Million)
  • FIG. 30 Others market estimates, 2017 - 2028 (USD Million)
  • FIG. 31 Regional marketplace: Key takeaways
  • FIG. 32 Global neurological biomarkers market: Regional movement analysis
  • FIG. 33 North America neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 34 The U.S. neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 35 Canada neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 36 Europe neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 37 The U.K. neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 38 Germany neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 39 France neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 40 Spain neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 41 Italy neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 42 Asia Pacific neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 43 Japan neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 44 China neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 45 India neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 46 South Korea neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 47 Australia neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 48 Latin America neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 49 Brazil neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 50 Mexico neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 51 Argentina neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 52 MEA neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 53 South Africa neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 54 Saudi Arabia neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 55 UAE neurological biomarkers market, 2017 - 2028 (USD Million)
  • FIG. 56 Strategy framework
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!